Alzheimer's Disease: Drugs
Commons · Question 61301 · Tabled 19 Jun 2025 · Department of Health and Social Care · Official record
Answered 25 Jun 2025
Question
Asked by Andrew Snowden
To ask the Secretary of State for Health and Social Care, if he will publish the cost-benefit modelling for the prescription of (a) donanemab and (b) lecanemab for patients with early-stage Alzheimer’s disease.
Answer
Answered by Karin Smyth, 25 Jun 2025
The National Institute for Health and Care Excellence has published the company’s evidence submission, which includes the company’s evidence on costs and benefits, and the external assessment group report, which assesses the company’s evidence submission ...